Development of standard clinical endpoints for use in dengue interventional trials

Dengue is a major public health problem worldwide. Although several drug candidates have been evaluated in randomized controlled trials, none has been effective and at present, early recognition of severe dengue and timely supportive care are used to reduce mortality. While the first dengue vaccine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tomashek, Kay M. (VerfasserIn) , Jänisch, Thomas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: October 4, 2018
In: PLoS neglected tropical diseases
Year: 2018, Jahrgang: 12, Heft: 10, Pages: 1-21
ISSN:1935-2735
DOI:10.1371/journal.pntd.0006497
Online-Zugang:Verlag, Volltext: https://doi.org/10.1371/journal.pntd.0006497
Verlag, Volltext: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006497
Volltext
Verfasserangaben:Kay M. Tomashek, Bridget Wills, Lucy Chai See Lum, Laurent Thomas, Anna Durbin, Yee-Sin Leo, Norma de Bosch, Elsa Rojas, Kim Hendrickx, Martin Erpicum, Liane Agulto, Thomas Jaenisch, Hasitha Tissera, Piyarat Suntarattiwong, Beth Ann Collers, Derek Wallace, Alexander C. Schmidt, Alexander Precioso, Federico Narvaez, Stephen J. Thomas, Robert Edelman, João Bosco Siqueira, M. Cristina Cassetti, Walla Dempsey, Duane J. Gubler

MARC

LEADER 00000caa a2200000 c 4500
001 1671160029
003 DE-627
005 20230428190745.0
007 cr uuu---uuuuu
008 190812s2018 xx |||||o 00| ||eng c
024 7 |a 10.1371/journal.pntd.0006497  |2 doi 
035 |a (DE-627)1671160029 
035 |a (DE-599)KXP1671160029 
035 |a (OCoLC)1341235372 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Tomashek, Kay M.  |e VerfasserIn  |0 (DE-588)1192681533  |0 (DE-627)1671159993  |4 aut 
245 1 0 |a Development of standard clinical endpoints for use in dengue interventional trials  |c Kay M. Tomashek, Bridget Wills, Lucy Chai See Lum, Laurent Thomas, Anna Durbin, Yee-Sin Leo, Norma de Bosch, Elsa Rojas, Kim Hendrickx, Martin Erpicum, Liane Agulto, Thomas Jaenisch, Hasitha Tissera, Piyarat Suntarattiwong, Beth Ann Collers, Derek Wallace, Alexander C. Schmidt, Alexander Precioso, Federico Narvaez, Stephen J. Thomas, Robert Edelman, João Bosco Siqueira, M. Cristina Cassetti, Walla Dempsey, Duane J. Gubler 
264 1 |c October 4, 2018 
300 |a 21 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.08.2019 
520 |a Dengue is a major public health problem worldwide. Although several drug candidates have been evaluated in randomized controlled trials, none has been effective and at present, early recognition of severe dengue and timely supportive care are used to reduce mortality. While the first dengue vaccine was recently licensed, and several other candidates are in late stage clinical trials, future decisions regarding widespread deployment of vaccines and/or therapeutics will require evidence of product safety, efficacy and effectiveness. Standard, quantifiable clinical endpoints are needed to ensure reproducibility and comparability of research findings. To address this need, we established a working group of dengue researchers and public health specialists to develop standardized endpoints and work towards consensus opinion on those endpoints. After discussion at two working group meetings and presentations at international conferences, a Delphi methodology-based query was used to finalize and operationalize the clinical endpoints. Participants were asked to select the best endpoints from proposed definitions or offer revised/new definitions, and to indicate whether contributing items should be designated as optional or required. After the third round of inquiry, 70% or greater agreement was reached on moderate and severe plasma leakage, moderate and severe bleeding, acute hepatitis and acute liver failure, and moderate and severe neurologic disease. There was less agreement regarding moderate and severe thrombocytopenia and moderate and severe myocarditis. Notably, 68% of participants agreed that a 50,000 to 20,000 mm3 platelet range be used to define moderate thrombocytopenia; however, they remained divided on whether a rapid decreasing trend or one platelet count should be case defining. While at least 70% agreement was reached on most endpoints, the process identified areas for further evaluation and standardization within the context of ongoing clinical studies. These endpoints can be used to harmonize data collection and improve comparability between dengue clinical trials. 
650 4 |a Blood plasma 
650 4 |a Hematocrit 
650 4 |a Hemodynamics 
650 4 |a Hemorrhage 
650 4 |a Hepatitis 
650 4 |a Myocarditis 
650 4 |a Platelets 
650 4 |a Thrombocytopenia 
700 1 |a Jänisch, Thomas  |d 1968-  |e VerfasserIn  |0 (DE-588)121170993  |0 (DE-627)705277275  |0 (DE-576)182736911  |4 aut 
773 0 8 |i Enthalten in  |a Public Library of Science  |t PLoS neglected tropical diseases  |d Lawrence, Kan. : PLoS, 2007  |g 12(2018,10) Artikel-Nummer e0006497, 21 Seiten  |h Online-Ressource  |w (DE-627)568915356  |w (DE-600)2429704-5  |w (DE-576)281703248  |x 1935-2735  |7 nnas 
773 1 8 |g volume:12  |g year:2018  |g number:10  |g pages:1-21  |g extent:21  |a Development of standard clinical endpoints for use in dengue interventional trials 
856 4 0 |u https://doi.org/10.1371/journal.pntd.0006497  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006497  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190812 
993 |a Article 
994 |a 2018 
998 |g 121170993  |a Jänisch, Thomas  |m 121170993:Jänisch, Thomas  |d 910000  |d 912800  |d 50000  |e 910000PJ121170993  |e 912800PJ121170993  |e 50000PJ121170993  |k 0/910000/  |k 1/910000/912800/  |k 0/50000/  |p 12 
999 |a KXP-PPN1671160029  |e 3506363921 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 12.08.2019"],"language":["eng"],"recId":"1671160029","person":[{"family":"Tomashek","given":"Kay M.","display":"Tomashek, Kay M.","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Jänisch","given":"Thomas","roleDisplay":"VerfasserIn","display":"Jänisch, Thomas","role":"aut"}],"title":[{"title_sort":"Development of standard clinical endpoints for use in dengue interventional trials","title":"Development of standard clinical endpoints for use in dengue interventional trials"}],"physDesc":[{"extent":"21 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Public Library of Science"]},"id":{"issn":["1935-2735"],"eki":["568915356"],"zdb":["2429704-5"]},"origin":[{"publisherPlace":"Lawrence, Kan.","dateIssuedKey":"2007","publisher":"PLoS","dateIssuedDisp":"2007-"}],"recId":"568915356","corporate":[{"roleDisplay":"VerfasserIn","display":"Public Library of Science","role":"aut"}],"language":["eng"],"note":["Gesehen am 20.11.2020"],"disp":"Public Library of SciencePLoS neglected tropical diseases","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Neglected tropical diseases"}],"part":{"pages":"1-21","issue":"10","year":"2018","extent":"21","volume":"12","text":"12(2018,10) Artikel-Nummer e0006497, 21 Seiten"},"pubHistory":["1.2007 -"],"title":[{"title_sort":"PLoS neglected tropical diseases","title":"PLoS neglected tropical diseases"}]}],"name":{"displayForm":["Kay M. Tomashek, Bridget Wills, Lucy Chai See Lum, Laurent Thomas, Anna Durbin, Yee-Sin Leo, Norma de Bosch, Elsa Rojas, Kim Hendrickx, Martin Erpicum, Liane Agulto, Thomas Jaenisch, Hasitha Tissera, Piyarat Suntarattiwong, Beth Ann Collers, Derek Wallace, Alexander C. Schmidt, Alexander Precioso, Federico Narvaez, Stephen J. Thomas, Robert Edelman, João Bosco Siqueira, M. Cristina Cassetti, Walla Dempsey, Duane J. Gubler"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"October 4, 2018"}],"id":{"doi":["10.1371/journal.pntd.0006497"],"eki":["1671160029"]}} 
SRT |a TOMASHEKKADEVELOPMEN4201